Summary:
Medical & Behavioral Health Research, PC is conducting a phase 3, randomized, double blind, placebo controlled, parallel group, multi-center, fixed dose clinical trial evaluating the efficacy, safety and tolerability of cariprazine in patients with bipolar I depression.
Qualified Participants Must:
• Be between 18 to 65 years of age
•
Be previously diagnosed with Bipolar Disorder, currently depressed
Qualified Participants May Receive:
Free psychiatric and physical evaluations (ECG, blood test).
Compensation for time and travel if eligible.